J
Jiangsu GDK Biotechnology Co Ltd
SSE:688670
Jiangsu GDK Biotechnology Co Ltd
SSE:688670
Price:
19.45
CNY
-2.51%
Market Closed
Market Cap:
¥2.4B
Relative Value
The Relative Value of one Jiangsu GDK Biotechnology Co Ltd stock under the Base Case scenario is 13.31 CNY. Compared to the current market price of 19.45 CNY, Jiangsu GDK Biotechnology Co Ltd is Overvalued by 32%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
13.31
CNY
Overvaluation 32%
J
Multiples Across Competitors
Competitors Multiples
Jiangsu GDK Biotechnology Co Ltd Competitors
Jiangsu GDK Biotechnology Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
J
|
Jiangsu GDK Biotechnology Co Ltd
SSE:688670
|
2.4B CNY | 20.6 | -18.9 | -13.7 | -13.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
407.7B USD | 6.7 | 97.4 | 16 | 22.2 | |
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD | 462 374.5 | -2 631.9 | -2 389.6 | -2 389.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
208.4B USD | 5.7 | 27 | 15.4 | 15.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.3B USD | 6.3 | 21.8 | 13.5 | 16.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
125.9B USD | 10.5 | 31.9 | 24.1 | 25.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD | 5.7 | 18.3 | 13.7 | 15.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
71.1B AUD | 3.2 | 16.7 | 11.5 | 14.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.9B EUR | 11.4 | 36.5 | 39.7 | 40.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
